source
- Gray‑market copies of Lilly’s obesity drug retatrutide show weaker weight‑loss results, study findsA recent study examined the effectiveness of gray‑market versions of Eli Lilly’s triple‑agonist obesity drug retatrutide. The analysis found that patients using these unapproved copies experienced…
- Scribe Therapeutics’ early-stage IPO surges 43% as epigenetic cholesterol drug enters clinicScribe Therapeutics filed for an IPO while its lead epigenetic therapy moves into early clinical testing, a rare combination in a market that prefers later-stage, de-risked offerings. The company…